- Last sale
- Nov 12, 2026 · -3.90%
- Market cap
- $1.72B
- 107.24M shares
- Filings
- 1,021
Q3 2026+15.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−27.4% FY25 yoy
- $1.72B
- —
- 1.2×
- 1.1×
- 10.27%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2,198,237,000 | reported | |
| FY 2024 | 2024-12-31 | $1,901,979,000 | reported | |
| FY 2023 | 2023-12-31 | $1,243,336,000 | reported | |
| FY 2022 | 2022-12-31 | $843,769,000 | reported | |
| FY 2021 | 2021-12-31 | $612,401,000 | reported | |
| FY 2020 | 2020-12-31 | $455,865,000 | reported | |
| FY 2019 | 2019-12-31 | $380,833,000 | reported | |
| FY 2018 | 2018-12-31 | $301,034,000 | reported | |
| FY 2017 | 2017-12-31 | $154,584,000 | reported | |
| FY 2016 | 2016-12-31 | $5,421,000 | reported | |
| FY 2015 | 2015-12-31 | $1,253,000 | reported | |
| FY 2014 | 2014-12-31 | $9,757,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $25.01M | $25.01M | — | 104.99M sh | +8.2% | — |
| FY2024 | — | $0.00 | $0.00 | — | 97.03M sh | +3.4% | — |
| FY2023 | — | $0.00 | $0.00 | — | 93.86M sh | +6.7% | — |
Segments
LineFY2022ShareChange
US$747.10M80%—
Outside of U.S.$96.70M10%—
Total$933.01M
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR